From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America.
Latin America
colorectal cancer
hereditary
lynch syndrome
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
17
07
2018
revised:
14
09
2018
accepted:
19
09
2018
pubmed:
12
10
2018
medline:
2
11
2019
entrez:
11
10
2018
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and Argentina. We provide a global snapshot of the CRC patterns, how screening is performed, and compared/contrasted to the genetic profile of Lynch syndrome (LS) in the region. From the literature, we find that only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC, and also with a low adherence. We describe a genetic profile of LS, including a total of 2,685 suspected families, where confirmed LS ranged from 8% in Uruguay and Argentina to 60% in Peru. Among confirmed LS, path_MLH1 variants were most commonly identified in Peru (82%), Mexico (80%), Chile (60%), and path_MSH2/EPCAM variants were most frequently identified in Colombia (80%) and Argentina (47%). Path_MSH6 and path_PMS2 variants were less common, but they showed important presence in Brazil (15%) and Chile (10%), respectively. Important differences exist at identifying LS families in Latin American countries, where the spectrum of path_MLH1 and path_MSH2 variants are those most frequently identified. Our findings have an impact on the evaluation of the patients and their relatives at risk for LS, derived from the gene affected. Although the awareness of hereditary cancer and genetic testing has improved in the last decade, it is remains deficient, with 39%-80% of the families not being identified for LS among those who actually met both the clinical criteria for LS and showed MMR deficiency.
Identifiants
pubmed: 30303536
doi: 10.1002/ijc.31920
pmc: PMC6587543
doi:
Substances chimiques
MLH1 protein, human
0
MSH2 protein, human
EC 3.6.1.3
MutL Protein Homolog 1
EC 3.6.1.3
MutS Homolog 2 Protein
EC 3.6.1.3
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
318-326Informations de copyright
© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Rev Gastroenterol Peru. 2016 Jan-Mar;36(1):35-42
pubmed: 27131939
Genet Mol Biol. 2016 May 24;39(2):166-7
pubmed: 27223489
Fam Cancer. 2016 Jul;15(3):437-45
pubmed: 27007491
Cancer. 2018 Aug 1;124(15):3145-3153
pubmed: 29750335
Curr Opin Gastroenterol. 2010 Sep;26(5):466-70
pubmed: 20664346
Ann Glob Health. 2014 Sep-Oct;80(5):370-7
pubmed: 25512152
Lancet Oncol. 2013 Apr;14(5):391-436
pubmed: 23628188
Ann Glob Health. 2014 Sep-Oct;80(5):412-7
pubmed: 25512156
Fam Cancer. 2013 Jun;12(2):175-80
pubmed: 23443670
Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
Gastroenterology. 2008 May;134(5):1570-95
pubmed: 18384785
Fam Cancer. 2011 Dec;10(4):641-7
pubmed: 21681552
Rev Invest Clin. 2017 Mar-Apr;69(2):94-102
pubmed: 28453507
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Genes Chromosomes Cancer. 2018 Jul;57(7):350-358
pubmed: 29520894
Genet Mol Biol. 2014 Mar;37(1 Suppl):234-40
pubmed: 24764757
Front Oncol. 2016 Aug 24;6:189
pubmed: 27606285
Hum Mutat. 2016 Nov;37(11):1162-1179
pubmed: 27435373
Clin Genet. 2018 Jul;94(1):61-69
pubmed: 29286535
BMC Cancer. 2017 Sep 5;17(1):623
pubmed: 28874130
Int J Cancer. 2018 Dec 1;143(11):2800-2813
pubmed: 29987844
J Natl Compr Canc Netw. 2017 Dec;15(12):1465-1475
pubmed: 29223984
Cancer Med. 2017 Dec;6(12):3014-3024
pubmed: 29055968
Rev Med Chil. 2006 Oct;134(10):1221-9
pubmed: 17186090
Hered Cancer Clin Pract. 2013 Dec 18;11(1):18
pubmed: 24344984
Anticancer Res. 2012 Oct;32(10):4347-51
pubmed: 23060557
J Clin Oncol. 2017 Apr 1;35(10):1086-1095
pubmed: 28135145
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Ann Oncol. 2017 Sep 1;28(9):2286-2297
pubmed: 28911064
BMJ. 2017 Jan 13;356:i6673
pubmed: 28087510
Gut. 2017 Mar;66(3):464-472
pubmed: 26657901
Genet Mol Res. 2006 Jun 30;5(2):315-22
pubmed: 16819711
CA Cancer J Clin. 2018 May;68(3):217-231
pubmed: 29485237
Gut. 2017 Sep;66(9):1657-1664
pubmed: 27261338
PLoS One. 2013 Sep 06;8(9):e72091
pubmed: 24039736
Fam Cancer. 2018 Jul;17(3):395-402
pubmed: 29128931
Salud Publica Mex. 2016 Apr;58(2):104-17
pubmed: 27557369
Hum Mutat. 2011 Apr;32(4):407-14
pubmed: 21309036
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
JAMA Oncol. 2017 Apr 1;3(4):464-471
pubmed: 27978560
Gastroenterology. 2017 Jul;153(1):307-323
pubmed: 28600072
J Med Genet. 2010 Sep;47(9):579-85
pubmed: 20587412
BMC Cancer. 2012 Feb 09;12:64
pubmed: 22321913
BMC Med Genet. 2018 Feb 20;19(1):26
pubmed: 29458332
Biomedica. 2005 Sep;25(3):315-24
pubmed: 16276679
Fam Cancer. 2010 Jun;9(2):109-15
pubmed: 19763885